Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline Review, H1 2020’, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)

– The report reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects

– The report assesses Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ahn-Gook Pharmaceutical Co Ltd

CalyGene Biotechnology Inc

Cancer Advances Inc

Changchun Serene Pharmaceutical Co Ltd

Chong Kun Dang Pharmaceutical Corp

Cinclus Pharma AG

CJ HealthCare Corp

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Hanmi Pharmaceuticals Co Ltd

Hunan Mingrui Pharmaceutical Co Ltd

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Renexxion LLC

Sam-A Pharm Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

Trio Medicines Ltd

XuanZhu Pharma Co Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview

Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Reflux Esophagitis (Gastroesophageal Reflux Disease) Companies Involved in Therapeutics Development

Ahn-Gook Pharmaceutical Co Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Handa Pharmaceuticals LLC

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Sam-A Pharm Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Reflux Esophagitis (Gastroesophageal Reflux Disease) Drug Profiles

(esomeprazole + sodium bicarbonate) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azeloprazole sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceclazepide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-20043 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-30065 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

colesevelam Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole DR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esomeprazole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-17DT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HND-009 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilaprazole DR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IYHCR-17 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-1366 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole DR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000774 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-15001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vonoprazan Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-842 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XY-066 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YY-DXR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Reflux Esophagitis (Gastroesophageal Reflux Disease) Dormant Projects

Reflux Esophagitis (Gastroesophageal Reflux Disease) Discontinued Products

Reflux Esophagitis (Gastroesophageal Reflux Disease) Product Development Milestones

Featured News & Press Releases

Aug 28, 2019: Sales of new gastric acid blocker K-Cab top 10 billion

May 09, 2019: Ironwood Pharmaceuticals to highlight IW-3718 data at Digestive Disease Week 2019

Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China

Mar 27, 2019: CJ Healthcare releases P3 trial results for gastroesophageal reflux treatment

Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American College of Gastroenterology 2018 Annual Scientific Meeting

Jul 06, 2018: Ministry approves CJ Healthcares gastroesophageal reflux treatment

Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare

Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018

May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018

Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD

Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017

Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by CalyGene Biotechnology Inc, H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Dormant Projects, H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Dormant Projects, H1 2020 (Contd..2), H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Discontinued Products, H1 2020

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports